DOCSLIB.ORG

Sustainability Report 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sustainability Report 2010 Sustainability Report 2010 Janssen Pharmaceutica NV Foreword The pharmaceutical sector in 2010 was again con- The above information is also clearly reflected in our fronted with very significant cuts in the budgets set annual figures. The turnover increased by 196 million aside for medication, both at home and abroad. euro compared to 2009, while the other operating TThese cuts were mainly a consequence of the eco- income increased by 95 million euro in 2010. Profit nomic crisis and the credit problems in a number of amounted to 22 million euro, which is 26 million euro countries during 2008 and 2009, and they also have more than in 2009. The investment figures for both an impact on Janssen. The price reductions imposed the campus in Beerse and the campus in Geel de- in the past years, and the taxation on prescription monstrate that we still firmly believe in Belgium as medicine turnover continue to negatively impact our our place of business. In 2010, we spent more than 1 profitability. billion euro on Research & Development, in addition to substantial sums on infrastructure and new tech- Despite the loss in income due to the expiry of major nologies. In Beerse, for example, major investments patents in recent years, Janssen has continued to were made in a production line for the production of invest in Research & Development, and this has McNeil products and in the necessary adjustments to resulted in even more pressure on the company’s the building in order to prepare it for the move of our profitability. The pharmaceutical industry is currently sister company Tibotec-Virco’s employees from characterized by a decline in the efficiency and pro- Mechelen to Beerse. The major investment project in ductivity of efforts with regard to Research & Geel was the further completion of the new Pilot Development. Janssen has not escaped from this Plant and the associated utilities. general trend. In order to address this negative evo- lution, Janssen has created the Office for Campus In addition, industrial land was purchased in La Strategy & Growth (OCS) in 2010. This team has Louvière with the aim of building a European already taken a number of initiatives in the context of Distribution Center for the J&J Pharmaceuticals Open Innovation in the meantime. For example, the Group, which is currently under construction. In active search for different forms of cooperation with Diegem, an office building was purchased and reno- interesting third parties, and offering some of these vated and will be made available to the Belgian com- parties the possibility of establishing themselves on panies of the J&J MD&D Group; the MD&D Group will our company site. move here in the course of 2011. In the context of the reduction of the number of Johnson & Johnson the acquisition of the operating sites on a global scale, our colleagues from Dutch company Crucell by Janssen-Cilag Benelux, GCO and J&J Consumer J&J, an operation that was moved from Berchem to Beerse 2 last year. The high successfully completed concentration of know-how in a limited number of early in 2011, is probably locations in Belgium is already important in itself. But even more important, and the major benefit is that, from now on, all these that offers us the perspec- departments and services will work even closer tive of developing into one together in order to obtain a whole that is greater of the world players in the than the sum of its components. This should give us area of vaccines in time. the assurance that we are in a strong position to face the future. Taking the difficult economic conditions and numer- ous challenges of the markets into account, we are We can also report plenty of positive news in the area now focusing more than ever on our main objective: of the development of new medicines in 2010. For To develop new drugs against complex diseases for example, a total of no less than four registration which insufficient effective treatment is currently applications were submitted in the USA and/or available. Janssen in Belgium is playing a leading role Europe. These are also important files, including the in this respect, and remains a major player in the INCIVO (telaprevir) file, a pioneering product for social and economic areas, as well as a world player in patients suffering from hepatitis C, and the ZYTIGA drug research, development and production. But all (abiraterone) file, a promising product for patients this is only possible thanks to the motivation and with prostate cancer that has been approved by the efforts of our employees in all the areas in which we American FDA in the meantime. With these medi- operate. Their talents continue to be our greatest cines, we are setting a new standard in the treatment assets for our continued success in the future. of these diseases. There is also fresh hope for HIV/ AIDS patients, because we have a very promising new medicine in the pipeline for them as well, EDURANT (rilpivirine), a product that was discovered on our campus. The management is confident that these important products will soon meet the needs of a great many patients, and will be able to help fill some of the still numerous gaps in the health care sector. In addition, major cooperation agreements were signed with a significant number of academic institu- tions and external companies. We mention here, for example, the cooperation with the renowned Koch Tom Heyman Institute in the USA, which holds great promises for Managing Director future innovations in the battle against cancer. But Janssen Pharmaceutica NV D2011/1060/04 JANSSEN PHARMACEUTICA - SUSTAINABILITY REPORT 2010 1 Patients Janssen Pharmaceutica’s most important The global integration of Johnson & Johnson’s contribution to society is the discovery, pharmaceutical research activities also pro- development and production of new drugs. vides other departments based in Beerse JExpenditure on Research & Development with plenty of opportunities for intensive increased slightly in 2010, and amounted to cooperation and support. The possible 1,067 million euro. The basis of our R&D establishment of external partner compa- activities remains the search for new medi- nies at the campus will also have an enrich- cines with a high added-value that are not ing impact on our own R&D staff. In addition only safe and efficient, but also satisfy unmet to the close cooperation with academic cen- medical needs. This means that we focus pri- ters, biotech companies and other pharma- marily on those disease areas for which no ceutical partner companies, a number of effective treatments are available yet. agreements were entered into in 2010 that are particularly important for our future. The Janssen R&D departments in Beerse These include agreements with WuXi mainly focus on the research into substances PharmaTech, which operates in China and intended for disorders in the field of neuro- the USA in the area of pre-clinical services, sciences (psychiatry and degenerative disor- the Koch Institute in the USA, which is con- ders), oncology (remedies for slowing down centrating on cancer research, and Neuro- the growth of tumors) and infectious diseas- Search, a Danish company active in the field es, areas in which we currently hold a leading of neurological research. In our own coun- position worldwide, or in which we intend to try, a collaboration with the Flemish Institute become market leaders in the future. for Biotechnology was announced, with the Diagnostic tools will also become an impor- aim of developing new medicines for the tant research area for us. Our colleagues treatment of psychiatric and neurodege- from Tibotec-Virco Virology, who have been nerative disorders. based on the campus in Beerse since mid- 2010, are concentrating on the discovery In 2010, several files of important new pro- and development of pharmaceutical products ducts were submitted to the authorities for an and innovative treatment methods that can initial or for additional registration. In addi- be useful in the treatment of patients with tion, our company was involved in the devel- chronic infectious diseases, such as HIV/ opment and/or production of a number of AIDS, hepatitis C and tuberculosis. substances by their group associations. 2 JANSSEN PHARMACEUTICA - SUSTAINABILITY REPORT 2010 Products for which the registration application was submitted in 2010: XEPLION® (paliperidone palmitate) schizophrenia 1250 INCIVO® (telaprevir) hepatitis C ZYTIGA® (abiraterone acetate) prostate cancer 1000 1,137 EDURANT® (rilpivirine) HIV/aids 1,106 1,067 1,031 XARELTO® (rivaroxaban) venous thrombosis and atrial fibrillation 750 REMICADE® (infliximab) pediatric ulcerative colitis INVEGA® (paliperidone) pediatric schizophrenia 500 YONDELIS® (trabectedine) ovarian cancer 250 NUCYNTA ER® (tapentadol) chronic pain SIMPONI® (golimumab) rheumatoid arthritis 0 Progress was booked in the research into the following substances: 2007 2008 2009 2010 Bapineuzumab IV Alzheimer’s disease Canagliflozin type 2 diabetes Evolution of R&D investments (in million euros) CNTO136 (sirukumab) autoimmune diseases DACOGEN™ (decitabine) cancer treatment Fulranumab pain relief CNTO328 (siltuximab) cancer treatment TMC207 tuberculosis TMC435 (simeprevir) hepatitis C In the calendar year 2010, 42 new patent applications were submitted under the name Indicators 2007 2008 2009 2010 of Janssen Pharmaceutica NV. Numerous R&D investments (in million euros) 1,137 1,106 1,031 1,067 checks to ensure patient well-being and Product responsibility: safety are carried out in both the initial stages system available Yes Yes Yes Yes of research and during the development, production and sale of our medicines. The company keeps the various authorities Subject Programs Audit up-to-date on progress and applies for the Product responsibility Quality Assurance, GLP, GMP Internal and external, necessary licenses that are required by law. Internal reporting international For example, a new environmental permit Regulatory files was obtained for the expansion of our sites Pharmacovigilance with the activities of Tibotec-Virco, Janssen- Cilag Benelux and J&J Consumer.
Load more

Recommended publications
  • Special Edition Inside
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Inside: Feature articles from 2014-2015 Special Edition VISIT THE ASPET CAREER CENTER TODAY! WWW.ASPET.ORG/CAREERCENTER/ 4 5 12 21 30 41 WHAT YOU NEED: ASPET’S CAREER CENTER HAS IT 52 Jobseekers: Employers: No registration fee Searchable résumé database Advanced search options Hassle-free posting; online account management tools 61 Sign up for automatic email notifi cations of new jobs that Reach ASPET’s Twitter followers (over 1,000), match your criteria LinkedIn Members (over 2,000), and email subscribers (over 4,000) Free & confi dential résumé posting 71 Post to just ASPET or to entire NHCN network Access to jobs posted on the National Healthcare Career Network (NHCN) Sign up for automatic email notifications of new résumés that match your criteria Career management resources including career tips, coaching, résumé writing, online profi le development, Job activity tracking and much more ASPET is committed to your success: The ASPET Career Center is the best resource for matching job seekers and employers in the pharmacology and related health science fi elds. Our vast range of resources and tools will help you look for jobs, fi nd great employees, and proactively manage 9650 Rockville Pike, Bethesda, MD 20814-3995 your career goals. Main Office: 301.634.7060 www.aspet.org ASPET Career Center Full Page Ad 2015 Updated.indd 1 1/15/2016 3:18:16 PM The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. THE PHARMACOLOGIST VISIT THE ASPET CAREER CENTER TODAY! PRODUCTION TEAM Rich Dodenhoff Catherine Fry, PhD WWW.ASPET.ORG/CAREERCENTER/ Judith A.
    [Show full text]
  • Contract Reduces Scientists' Workload
    MAINTENANCE HPLC set-up with system layout (flat screen). On the left, a Waters Micromass 996 with Photo Diode Array detection. Janssen Pharmaceuticals outsources central management of 17,000 lab instruments COMPREHENSIVE MAINTENANCE contract reduces scientists’ workload Els van den Brink, Images: FOODnote Janssen Pharmaceuticals Beerse, a J&J subsidiary, has Not only has Beerse maintenance been outsourced, but outsourced the maintenance of all its lab equipment. The also equipment from the Janssen-labs in Geel (raw materials production) and Merksem (clinical facility). After eighteen months decision has big advantages; the equipment’s maintenan- and proven success, J&J is rolling this approach out to other ce status is clear, maintenance is more efficient, up-time is European sites. In Belgium, 17,000 lab instruments are centrally increased and costs are lower thanks to economies of scale managed – 14,000 of them in Beerse. Outsourcing doesn’t just with existing suppliers. But above all, outsourcing reduces relieve the lab managers of a task, but also provides them with a the administrative workload for lab managers and analysts. complete overview of their equipment maintenance strategy so they can manage their equipment based on Key Performance 2 LABinsights | December 2017 MAINTENANCE Indicators (KPIs). Scientists can call on a dedicated team Pilot study of qualified engineers onsite who address acute problems The 14,000 instruments in Beerse are housed in 12 buildings. affecting critical equipment. Valued at half a billion euros, this equipment costs 10 million euro a year in maintenance, Van Deun says. Centralizing the KPIs maintenance of so much equipment is a major effort, so it was At Janssen, Senior Manager of Laboratory Services Jan Van done in phases.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Chinese Terracotta Warriors
    28 How Paul Janssen’s Drugs Saved the CCHHIINNEESSEE TTEERRRRAACCOOTTTTAA WWAARRRRIIOORRSS Rebecca J. Anderson The Chinese Terracotta Army, dating from approximately the late third century BCE, was discovered on March 29, 1974 to the east of Xi’an in Shaanxi Province, China. Photo: Shutterstock The Pharmacologist • March 2015 29 Chinese museum officials gazed with dismay at their Janssen label (3). These included repackaging and priceless army of ancient statues. For 22 centuries, the distributing generic penicillin and sulfonamides, which terracotta warriors had been protected and preserved in the were increasingly in demand after the war. Paul’s mother, soil of China’s Yellow River valley (1). Now, less than 20 Margriet Fleerakers, served as office manager and also years after these old soldiers emerged from their supervised the production line, including quality control (3). subterranean fortress, many of them had become infected Paul finished high school in 1943. To avoid forced and were suffering from a mysterious rash (2). Local labor in the German factories, he secretly enrolled in archeologists suspected the warriors’ moldy rash was due to college (at the age of 16) with the help of his uncle, Emiel fungi, but they lacked specialized laboratory equipment and Janssen (3). The 12 Jesuit teachers at the Faculté Notre- had only limited expertise to diagnose and treat the ailment. Dame de la Paix in Namur, Belgium, offered intensive The detective who stepped forward to solve this courses in physics, biology, philosophy, and chemistry to a mystery and thwart an archeological catastrophe was an handful of students, including Paul, without the knowledge unlikely hero: a businessman, physician, and scientist who of the German occupiers (2, 3).
    [Show full text]
  • Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20
    Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20 RAAP België - Rapport 125 Beheerboerderij Weerstandersstraat, Beerse Archeologienota Archeologisch Vooronderzoek Verslag van de Resultaten Bureauonderzoek – 2017H20 Nazareth 2017 0 Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20 Colofon Opdrachtgever: Agentschap voor Natuur en Bos Titel: Beheerboerderij Weerstandersstraat Beerse Archeologienota Archeologisch Vooronderzoek Bureauonderzoek - 2017H20 Status: Definitief Datum: 20 september 2017 Auteur: Hannes Van Crombrugge Projectcode: 2017H20 Raapproject: BEWE01 Erkend archeoloog: RAAP België (OE/ERK/Archeoloog/2016/00154) Bewaarplaats documentatie: RAAP België, Steenweg Deinze 72, 9810 Nazareth Bevoegd gezag: agentschap Onroerend Erfgoed RAAP België BVBA Steenweg Deinze 72 9810 Nazareth telefoon: 09/311 56 20 - 0498/44 16 99 E-mail: [email protected] © RAAP België bvba, 2017 RAAP België aanvaardt geen aansprakelijkheid voor eventuele schade voortvloeiend uit het gebruik van de resultaten van dit onderzoek of de toepassing van de adviezen. 1 Beheerboerderij Weerstandersstraat, Beerse Archeologienota 2017H20 Inhoudsopgave Inhoudsopgave ........................................................................................................................................ 2 Samenvatting ........................................................................................................................................... 3 1 Verslag van resultaten: bureauonderzoek 2017H20 ......................................................................
    [Show full text]
  • PROVINCIE ANTWERPEN BESTUURLIJK ARRONDISSEMENT ANTWERPEN Pagina 1 Van 48 PROVINCIE ANTWERPEN Datum: 17/08/2017
    PROVINCIE ANTWERPEN Datum: 17/08/2017 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) D tot. C O diagn bijk erk opm V - V V + (V 1bis) C B C M C H CB AW CB AW B CB AW M BEG CAP BESTUURLIJK ARRONDISSEMENT ANTWERPEN VZW Emmaüs DE GROTE ROBIJN Korte Sint-Annastraat 4 2000 Antwerpen 16 23 Telefoon: 03 231 25 75 12-18j 0-18j j-m j-m Fax: E-mail: [email protected] VER Zorgbedrijf Antwerpen CENTRA BIJZONDERE JEUGDZORG ZORGBEDRIJF ANTWERPEN Ballaarstraat 35 53 2018 Antwerpen 25 43 4 3 3 Telefoon: 03 334 44 50 0-18j 0-18j 0-18j j-m j-m j-m Fax: E-mail: [email protected] AFDELINGEN: PROVINCIE ANTWERPEN BESTUURLIJK ARRONDISSEMENT ANTWERPEN Pagina 1 van 48 PROVINCIE ANTWERPEN Datum: 17/08/2017 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) D tot. C O diagn bijk erk opm V - V V + (V 1bis) C B C M C H CB AW CB AW B CB AW M BEG CAP 18 3 DE WENDING 13 0-18j j-m Lamorinièrestraat 236 12-18j j-m 2018 Antwerpen 29 3 PENNSYLVANIA FOUNDATION 13 0-18j j-m Gouverneur Holvoetlaan 28 0-18j j-m 2100 Antwerpen VZW Elegast ELEGAST Belgiëlei 203 20 158 2018 Antwerpen 12 15 6-18j 94 32 6 26 j-m Telefoon: 03 286 75 25 0-12j 0-18j 0-18j 0-18j j-m j-m j-m j-m Fax: E-mail: [email protected] AFDELINGEN: PROVINCIE ANTWERPEN BESTUURLIJK ARRONDISSEMENT ANTWERPEN Pagina 2 van 48 PROVINCIE ANTWERPEN Datum: 17/08/2017 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) D tot.
    [Show full text]
  • Ravels - Tilburg PPEERDRD Ilburg Ravelsravels -- Ttilburg Monumental Statue of Renier N12N12
    Baarle-Hertog/Nassau N 15 Merksplas - i Tourism & UiT Hoogstraten1 Beguinage / Beguinage Museum 2 Taxandria Museum ON RIM IO M T U • A P N W D O I A R L L D H E • L R 3 I A T I ONIO A D RIM M G N T U Castle of E • A N O P • W PA E M D T O I RIMOIN A R L L D H E • L R A IT I A D G N Some statues you should absolutely not miss E O •P M ATRIMOINE the Dukes of Brabant Baarle-Hertog/Nassau N 15 4 Meduceum Renier Snieders (1930) 5 On the Patersplein (Monk’s Centre of cultural life ‘de Warande’ square) you will find the 14 6 City hall / Archives monumental statue of Renier Snieders. The statue was made BaBaarlarle-Hee-Hertog/Nrtog/Nassau ! Breda N119 7 Marketplace / St Peter’s Church as a memorial for this Dutch 13 N KAMPHEIDE doctor and writer. Snieders KAMPHEIDE ZWART WATER ZWART WATER 23 ONIO M IM UN TR D A IA • P L W O R • L L D A I H D E R N IT O A M G E E• IN Merksplas - PATRIMO Tip Hoogstraten DOMBERGHEIDE DOMBERGHEIDE 8 He izide ENGELAND was born in 1812 in Bladel, The ENGELAND National Playing e Heizid Ravels - Tilburg 22 NIEUWE BOSSEN NIEUWE BOSSEN Kas telei DEN DOOLHOF DEN DOOLHOF n dekensweg Vel PPEEERRDDSVVEEN 21 Ko n Have a walk around Turnhout and E MerksplasMeMerksplrksplasas 20 lis abe HoogsHoogsHoogsttratentratenen Steenweg op Merksplas th Netherlands, but later had a le Wouwerstraat i Oosthoven NN124124 wg op St RavelsRavels -- TTilburgilburg umlaan bile N12N12 u 24 J Plamaten19 einstraat f Font ree nend Til- e Begi Koning Albertstraat 22 n N 25 elestr NIO M MOO NOI MUU RI I M N N T R D D 1 A T AI t I • • P A LA • P L W W W W W O O O O R • • R L • L L D L D A I A I H H D E D R E N I R N TI O AT M O GA E M EG I E •EPAT O NNI 18 •PARTIRMIMO ai Beginhof nsstraa Hoveniersstraat aa e Ka Gul K e FIFIFILLILIPPIPKKEEKNENSVNSVISVIJIJVJVVEERER let de brand new signposting w densporenlei aste t Card Museum Ka ieu ndek N el Patersstraat dreef Li rel Oomst Brugstraat at 23 straat tra doctor’s practice in Turnhout.
    [Show full text]
  • Archeologische Begeleiding Verkaveling Beekakkers in Beerse
    ADAK RAPPORT 4 Archeologische begeleiding verkaveling Beekakkers in Beerse S. DELARUELLE & J. VAN DONINCK De Archeologische dienst Antwerpse Kempen is een projectvereniging van de gemeenten Beerse, Oud-Turnhout, Turnhout en Vosselaar met steun van de Vlaamse gemeenschap en de provincie Antwerpen. Colofon Opdrachtgever Hermans BVBA Project Beerse-Beekakkers Projectcode 07004 Vergunning 2007/46/13506 Auteurs Stephan Delaruelle & Jef Van Doninck Kaarten & plannen Stephan Delaruelle (©NGI/GIS Vlaanderen) Foto’s & tekeningen Stephan Delaruelle Omslagontwerp Hanna Maes ISBN / © AdAK , december 2007 Niets uit deze uitgave mag worden verveelvoudigd en/of openbaar gemaakt door middel van druk, fotokopie, microfilm of op welke andere wijze dan ook, zonder voorafgaande schriftelijke toestemming van de Archeologische Dienst Antwerpse Kempen. Beerse-Beekakkers AdAK Samenvatting Op 10 mei 2007 werd door de Archeologische Dienst Antwerpse Kempen (AdAK) in samenwerking Hermans BVBA een archeologische begeleiding van de aanleg van de wegkoffers uitgevoerd binnen de verkaveling Beekakkers aan de Beekakkerstraat te Beerse. Tijdens het onderzoek werd de ontgraving van de centraal gelegen wegkoffer opgevolgd alsook de sanering van de achterliggende gebieden, waarbij in totaal ca. 1500 m2 werd onderzocht. Tijdens het onderzoek werden geen archeologisch relevante sporen vastgesteld. Opmerkelijk was ook dat natuurlijke sporen grotendeels ontbraken. Doordat het plangebied tot voor kort in gebruik was als kwekerij voor buxusplanten, waren in de onaangeroerde bodem groene en oranje verkleuringen af te lezen, die vermoedelijk te maken hebben met de het gebruik van meststoffen en insecticiden. In het bodemprofiel was ook af te lezen dat een groot gedeelte van het terrein was afgegraven en omgezet bij de inrichting van het plantenbedrijf, zoals ook door de eigenaar was aangegeven.
    [Show full text]
  • Bijlagen.Pdf
    Bijlagen Inhoud Bijlage 1: Het hoe en waarom van een ruimtelijk structuurplan..........................................................7 1.1. Het wetgevend kader.........................................................................................................................7 1.1.1. Het decreet van 18 mei 1999 ...........................................................................................................7 1.1.2. Omzendbrief RO 97/02 over het gemeentelijk structuurplanningsproces........................................7 1.2. Aanpak structuurplanning Wuustwezel..........................................................................................8 1.2.1. Planningsmethodiek .........................................................................................................................8 1.2.2. Communicatie en organisatie.........................................................................................................10 Bijlage 2: Verbanden met het Ruimtelijk Structuurplan Vlaanderen (RSV)......................................14 2.1. Deelstructuren in het RSV ..............................................................................................................14 2.2. Buitengebied....................................................................................................................................14 2.2.1. Doelstellingen voor het buitengebied .............................................................................................14 2.2.2. Functies in het buitengebied ..........................................................................................................15
    [Show full text]
  • Book Review Paul Janssen
    BOOK REVIEW PAUL JANSSEN: PIONEER IN PHARMA & IN CHINA By Geerdt Magiels, Dundee: Dundee University Press, 2008, 258 pp. (incl. appendices and bibliography), £15.00, ISBN 978-1-84586-53-0 The history of Janssen Pharmaceutica and its evolvement in China is central to this homage to Paul Janssen, who set up the company in 1953; led it through a merger with Johnson & Johnson in 1961; built up relations with China from the 1960s onwards; and left clear footprints on its research agenda and company management style. The book owes its existence to Paul Janssen, who commissioned it to the author Geerdt Magiels. However, Janssen died shortly after their first meeting in 2003. The book aims to make known the scientific, business and human achievements of Paul Janssen. As such, there are scatterings of descriptions of major events in Janssen’s life; group photographs of important occasions and celebrations; and advice and adages on how to collaborate (for example, to have an open mind; to be creative; to allow local people to run the business; to work through friendship and compromise; to have patience; and to show mutual respect). The book gives corporate meaning to a global audience of the role of large pharmaceutical companies in developing countries. A role that involves the efforts made by such companies to advertise themselves as a bridge between rich and poor; their motivation by concerns for global health; and contributors to the well-being and development of people in developing countries. As a eulogy, this book can hardly be expected to meet academic standards.
    [Show full text]
  • Provinciaal Ruimtelijk Uitvoeringsplan
    provinciaal ruimtelijk uitvoeringsplan Voorstudie PRUP Retentiezone Laak Beerse Memorie van toelichting inclusief m.e.r.-screening Ruimtelijk planner: Steven Muylaert Dienst Ruimtelijke Planning Dienst Colofon Opdrachtgever: Dienst Ruimtelijke Planning Provincie Antwerpen Koningin Elisabethlei 22, 2000 Antwerpen tel.: 03 240 66 00 fax: 03 240 66 79 [email protected] contactpersoon: Stein Temmerman [email protected] 03/240.56.10 Opdrachthouder: D+A Consult nv Meiboom 26 1500 Halle contactpersoon: Steven Muylaert [email protected] 02/371.02.57 Dossiernummer: <ROPR/08-45> D+A Consult nv Inhoud 1. Inleiding ........................................................................................................................ 5 1.1. Aanleiding van de opdracht ....................................................................................... 5 1.2. Procesverloop .......................................................................................................... 5 2. Algemene situering ......................................................................................................... 6 2.1. Macro ..................................................................................................................... 6 2.2. Meso ...................................................................................................................... 6 2.3. Micro ...................................................................................................................... 7 3. Planningscontext ...........................................................................................................
    [Show full text]
  • Geografische Afbakening Van De Zorgregio's
    Geografische afbakening van de zorgregio’s Inhoudstafel 1. Situering .......................................................................................................................................... 3 2. Het huidige zorgregiodecreet .......................................................................................................... 4 3. Methodologie .................................................................................................................................. 5 4. Criteria voor afbakening .................................................................................................................. 7 4.1. Criteria voor afbakening op kleinstedelijk niveau ................................................................... 7 4.2. Criteria voor afbakening op regionaalstedelijk niveau ........................................................... 7 5. Voorstel tot afbakening per provincie op kleinstedelijk niveau ...................................................... 8 5.1. Provincie Limburg .................................................................................................................... 9 5.2. Provincie West-Vlaanderen ................................................................................................... 12 5.3. Provincie Vlaams-Brabant ..................................................................................................... 17 5.4. Provincie Oost-Vlaanderen .................................................................................................... 24
    [Show full text]